Filgotinib showed ⬇️ in spinal inflammation of AS pts after 12 weeks! ⭐️Subscores of the posterior elements, facet joints and vertebral bodies showed significant changes ⭐️no significant changes in spine fat, bone erosion or new bone formation Abs#OP0141 #EULAR2021 @RheumNow https://t.co/tcBFuxnu4n

Fatigue 35-80% of rheumatic pts! Excellent talk on fatigue in arthritis, SpA and systemic rheumatic disease! Abs#OP6875 #EULAR2021 @RheumNow How do you help pts manage fatigue?

➡️COMPLETE-AS = obs study of bDMARD-naive Canadians w/ active AS tx w/ ADA or nbDMARDS/NSAID. ➡️> overall⬇️in dz burden & shorter time to achieve therapeutic response w/ ADA. But, ADA pts had higher b/l dz OP0143 #EULAR2021 @RheumNow https://t.co/FpJmugsdVw

⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD ⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD ⭐️No overall increase in all CA: RTX, TOCI ⭐️Abatacept 1.21HR for all cancer, mainly NMSC ⭐️needs more data on JAKs, IL-17, IL-23 Abs#6916 #EULAR2021 @RheumNow

Efficacy & Safety of UPA after 1yr from SELECT-AXIS 1 study? ⭐️187 bDMARD-naive, active AS pts w/ inadeq resp to NSAID ⭐️82-85% txed w/ UPA 15mg QD achieved BASDAI50 or ASDAS LDA over 64w 🚫 new safety signal & ZERO VTE, MACE, TB, or deaths w/ UPA. OP0144 #EULAR2021 @RheumNow https://t.co/mFbgQjsD6f

➡️5 cases of single-dermatome Herpes Zoster in 4 patients treated w/ UPA 15 mg QD for active AS in SELECT-AXIS 1 ⭐️Do not forgot to vaccinate patients with 1st dose of Shingrix prior to starting a JAK-i. 2nd dose can be given after start of therapy OP0144 #EULAR2021 @RheumNow

Do you vaccinate ALL patients (even if less than 50 yo) with first dose of Shingrix prior to starting a JAK-i? #EULAR2021. @RheumNow

Interesting results from our post hoc analysis of #ASAS #PerSpA presented at #EULAR2021 by Dafne Capelusnik ⭐️Individual socioeconomic factors associated with poorer outcomes ⭐️Living in low GDP country associated with higher disease activity but paradoxically lower fatigue https://t.co/2SmKZPy8mw

Congratulations to everyone who made it through the day today.

Poster #POS1033: Integrated analysis of 4 IXE SPIRIT trials IR for TEAEs ⬇️ over time IR for SAEs low serious infections/malignancies/MACE/IBD ⬇️ #EULAR2021 @RheumNow https://t.co/tLyXwnBDTo

• https://ard.bmj.com/content/80/Suppl_1/789.1

GUS causes ⬇️ in serum collagen C1M (marker of joint response), C3M, C4M, C6M. Pts achieving ACR20 at week 24 had greater C1M reduction than non-responder. Abstract #POS1036 #EULAR2021 @RheumNow https://t.co/4JqbaMexuR https://t.co/gXltKn6qIc

• http://ow.ly/D1V050F2D5E

In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & radiographic progression. Safety comparable to 6mo/1yr data, similar between Q4W & Q8W dosing, & consistent w/ PsO trials. Poster #POS1027 #EULAR2021 @RheumNow https://t.co/nlcjOX7cBq https://t.co/NWqDTwfb4u

• https://ard.bmj.com/content/80/Suppl_1/783